Abstract
Treatment of human immunodeficiency virus (HIV) infection continues to be a challenge. Drug regimens that include two nucleoside reverse transcriptase inhibitors and a protease inhibitor are now the standard of care. These regimens require strict patient adherence and have numerous adverse effects at a high cost, so clinicians must continue to explore other therapeutic options. Hydroxyurea is a ribonucleotide reductase inhibitor that may have efficacy against HIV. We conducted a critical review of the literature to examine the utility of hydroxyurea-based drug combinations.
Original language | English |
---|---|
Pages (from-to) | 196-204 |
Number of pages | 9 |
Journal | Pharmacotherapy |
Volume | 19 |
Issue number | 2 |
DOIs | |
State | Published - 1999 |
ASJC Scopus subject areas
- Pharmacology (medical)